Publications: FMT (10)

2022

El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG. Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation - PubMed (nih.gov) Gastroenterology. 2022 Jun 13:S0016-5085(22)00625-4. doi: 10.1053/j.gastro.2022.06.020. Epub ahead of print. PMID: 35709830.

El-Salhy M, Mazzawi T, Hausken T, Hatlebakk JG. The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms - PubMed (nih.gov). Scand J Gastroenterol. 2022 Apr 29:1-10. doi: 10.1080/00365521.2022.2064725. Epub ahead of print. PMID: 35486073.

El-Salhy M, Mazzawi T, Hausken T, Hatlebakk JG. Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation - PubMed (nih.gov). Neurogastroenterol Motil. 2022 Mar 18:e14353. doi: 10.1111/nmo.14353. Epub ahead of print. PMID: 35302268.

2021

El-Salhy M, Kristoffersen AB, Valeur J, Casen C, Hatlebakk JG, Gilja OH, Hausken T. Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome - PubMed (nih.gov). Neurogastroenterol Motil. 2021 Jun 18:e14200. doi: 10.1111/nmo.14200. Epub ahead of print. PMID: 34145677.

El-Salhy M, Casen C, Valeur J, Hausken T, Hatlebakk JG. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome - PubMed (nih.gov). World J Gastroenterol 2021; 27(18): 2219-2237 [DOI: 10.3748/wjg.v27.i18.2219]

Mazzawi T, El-Salhy M, Lied GA, Hausken T. The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome - PubMed (nih.gov). Front Cell Infect Microbiol. 2021 May 12;11:524851. doi: 10.3389/fcimb.2021.524851. PMID: 34055657; PMCID: PMC8149964.